252 related articles for article (PubMed ID: 29424288)
1. The Ellipta
Jones TL; Neville DM; Chauhan AJ
Ther Deliv; 2018 Feb; 9(3):169-176. PubMed ID: 29424288
[TBL] [Abstract][Full Text] [Related]
2. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
4. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
5. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.
Yun Kirby S; Zhu CQ; Kerwin EM; Stanford RH; Georges G
COPD; 2016; 13(2):167-75. PubMed ID: 26516724
[TBL] [Abstract][Full Text] [Related]
6. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
Svedsater H; Dale P; Garrill K; Walker R; Woepse MW
BMC Pulm Med; 2013 Dec; 13():72. PubMed ID: 24314123
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
8. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD.
van der Palen J; Moeskops-van Beurden W; Dawson CM; James WY; Preece A; Midwinter D; Barnes N; Sharma R
Int J Chron Obstruct Pulmon Dis; 2018; 13():2515-2523. PubMed ID: 30174421
[TBL] [Abstract][Full Text] [Related]
10. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
[TBL] [Abstract][Full Text] [Related]
11. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W
Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177
[TBL] [Abstract][Full Text] [Related]
12. Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation.
Man KN; Tian Z; Lam DC; Wan JMF; Tan-Un KC
Int J Chron Obstruct Pulmon Dis; 2018; 13():1949-1963. PubMed ID: 29942127
[TBL] [Abstract][Full Text] [Related]
13. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
[TBL] [Abstract][Full Text] [Related]
14. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
15. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
[TBL] [Abstract][Full Text] [Related]
16. Device errors in asthma and COPD: systematic literature review and meta-analysis.
Chrystyn H; van der Palen J; Sharma R; Barnes N; Delafont B; Mahajan A; Thomas M
NPJ Prim Care Respir Med; 2017 Apr; 27(1):22. PubMed ID: 28373682
[TBL] [Abstract][Full Text] [Related]
17. Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease.
Feldman GJ; Galkin DV; Patel P; Collison KA; Sharma R
Chron Respir Dis; 2019; 16():1479973118815692. PubMed ID: 30789018
[TBL] [Abstract][Full Text] [Related]
18. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
Molimard M; Till D; Stenglein S; Singh D; Krummen M
Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
[TBL] [Abstract][Full Text] [Related]
19. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
Virchow JC; Weuthen T; Harmer QJ; Jones S
Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
[TBL] [Abstract][Full Text] [Related]
20. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
Henriet AC; Marchand-Adam S; Mankikian J; Diot P
Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
